Articles From: FDA Approves Dexcom Software with Artificial Pancreas Algorithm to Fed to stress test banks for 60% stock market dive, $110 oil


Dexcom, Inc., (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today that the U.S. Food and Drug Administration (FDA) has approved new software for the Dexcom G4 ® PLATINUM CGM.
Sign-up for FDA Approves Dexcom Software with Artificial Pancreas Algorithm investment picks
2014/12/12
By Angela Chen The U.S. Food and Drug Administration has approved Eli Lilly Co.'s Cyramza to treat non-small cell lung cancer, the most common type of lung cancer.
Sign-up for FDA approves Eli Lilly's Cyramza for lung cancer investment picks
Cerus Corporation (NASDAQ: CERS) today announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for plasma.
Sign-up for FDA Approves INTERCEPT Blood System for Plasma investment picks
Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi ® (ruxolitinib) for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
Sign-up for FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera investment picks
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle ® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.
Sign-up for FDA Approves New Styles of Allergan’s NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants investment picks
2014/12/23
By Maria Armental Danish drug maker Novo Nordisk A/S's (NVO) injectable diabetes drug has been approved in the U.S. to fight obesity, the Food and Drug Administration said Tuesday.
Sign-up for FDA Approves Novo Nordisk Diabetes Drug's Use to Fight Obesity investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for FDA Approves Teva’s GRANIX® (tbo-filgrastim) Injection for Self-Administration investment picks
NORTHBROOK, Ill., Oct.
Sign-up for FDA Clears Additional Viral Targets on Verigene Enteric Pathogens Test investment picks
SALT LAKE CITY, Dec.
Sign-up for FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021 investment picks
Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval for an Investigational Device Exemption (IDE) for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.
Sign-up for FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma investment picks
Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to existing exclusivity, Fast-Track status (an expedited development pathway) and Priority Review status (shortened review time for marketing applications) With half of the targeted 120 patients already recruited, top-line data from the ongoing RHB-105 first Phase III study in the U.S. is expected in the second quarter of 2015 RHB-105 is targeting a significantly broader indication than that of existing H.
Sign-up for FDA Grants QIDP Fast-Track Designation to RedHill Biopharma's Phase III H. pylori Drug RHB-105 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156038&ProfileId=051205&sourceType=1 SAN DIEGO, CA --
Sign-up for FDA Issues IND Number for Regen BioPharma's dCellVax Therapeutic Application, a Proposed Treatment for Breast Cancer investment picks
Generic biotech drugs took one step close to reality after a Food and Drug Administration advisory panel recommended the agency approve a Novartis AG (NVS) version of Amgen's Inc.'s (AMGN) drug Neupogen, according to media reports late Wednesday.
Sign-up for FDA panel recommends approval for first generic biotech drug investment picks
By Sean McLain NEW DELHI--The U.S. Food and Drug Administration revoked Ranbaxy Laboratories Ltd.'s right to produce generic versions of two drugs, including blockbuster heartburn drug Nexium--the latest blow to the Indian pharmaceutical company.
Sign-up for FDA revokes Ranbaxy's right to generic versions of Nexium, Valcyte investment picks
2015/1/12
The Food and Drug Administration plans to create a new Office of Pharmaceutical Quality to focus in part on manufacturing problems such as those that have beset generic companies that make extended-release versions of drugs.
Sign-up for FDA to Create New Drug Quality Office investment picks
Edison International, the parent company of Southern California Edison (SCE), reminds high school seniors that there’s still time to apply for the 2014-15 Edison Scholars Program , which offers $1.2 million in scholarships to high school seniors planning to pursue college studies in science, technology, engineering or math ( STEM ) fields.
Sign-up for Feb. 1 is Deadline to Apply for $1.2 Million Edison Scholars Program investment picks
2014/11/25
By Greg Robb, MarketWatch WASHINGTON (MarketWatch) -- Like the Reverend Mother in the Sound of Music who asked "how do you solve a problem like Maria," the Federal Reserve is asking the public how it should regulate a nonbank like GE Capital.
Sign-up for Fed asks: How do you regulate a nonbank like GE Capital? investment picks
2014/12/18
By Ryan Tracy and Scptt Patterson WASHINGTON--Regulators on Thursday handed Wall Street banks a temporary reprieve they have been clamoring for from a rule that forces them to pull out of certain risky investments.
Sign-up for Fed gives banks more time to sell private-equity, hedge-fund stakes investment picks
2014/12/3
By Eric Garcia, MarketWatch WASHINGTON (MarketWatch) -- A Federal Reserve official said Wednesday that the central bank is limited in its ability to promote financial stability.
Sign-up for Fed governor says central bank limited in promoting financial stability investment picks
2015/1/8
WASHINGTON--The Federal Reserve Bank of New York's failure to examine J.P. Morgan Chase & Co.'s investment unit ahead of the bank's 2012 "London whale" trading debacle stemmed from turf battles with other regulators, overreliance on J.P. Morgan's solid reputation and financial-crisis-related distractions, according to the Fed's watchdog.
Sign-up for Fed IG Report Sheds Light on 'London Whale' investment picks
2015/1/8
By Victoria McGrane and Ryan Tracy WASHINGTON--The Federal Reserve Bank of New York's failure to examine J.P. Morgan Chase & Co.'s investment unit ahead of the bank's 2012 "London whale" trading debacle stemmed from turf battles with other regulators, overreliance on J.P. Morgan's solid reputation and financial-crisis-related distractions, according to the Fed's watchdog.
Sign-up for Fed IG Report Sheds Light on 'London Whale' Incident--update investment picks
2014/12/9
The Federal Reserve is voting Tuesday on a proposal that would force systemically important banks to hold more capital than required under an international standard called Basel III.
Sign-up for Fed proposing big bank capital surcharges in excess of international standards investment picks
2014/10/23
By Steve Goldstein, MarketWatch WASHINGTON (MarketWatch)--The Federal Reserve will put banks through a stress test where the unemployment rate jumps to 10%, the stock market dives by 60%, and oil prices reach $110 a barrel, according to the methodology released Thursday.
Sign-up for Fed stress tests to put banks through 60% stock slide, $110 oil investment picks
2014/10/23
The Federal Reserve will put banks through a stress test where the unemployment rate jumps to 10%, the stock market dives by 60%, and oil prices reach $110 a barrel, according to the methodology released Thursday.
Sign-up for Fed to stress test banks for 60% stock market dive, $110 oil investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: FDA Approves Dexcom Software with Artificial Pancreas Algorithm to Fed to stress test banks for 60% stock market dive, $110 oil
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent